Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Metrics to compare | DYN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDYNPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −3.5x | −0.5x | |
PEG Ratio | 0.34 | 0.02 | 0.00 | |
Price/Book | 2.8x | 2.0x | 2.6x | |
Price / LTM Sales | - | 6.6x | 3.3x | |
Upside (Analyst Target) | 239.6% | 146.4% | 43.5% | |
Fair Value Upside | Unlock | 0.8% | 6.8% | Unlock |